WuXi Testing Launches China Medical Device Testing Center in Suzhou, Offering Globally Integrated, High-Standard Testing Solutions

VCBeat (WeChat ID: vcbeat) has learned that on November 16, 2018, WuXi AppTec’s Testing Division officially inaugurated and launched its Medical Device China Testing Center in Suzhou, Jiangsu Province.This marks the full-scale launch of WuXi AppTec’s medical device testing business in the Chinese market, which, together with its existing U.S. testing centers, establishes a globally integrated medical device testing platform.The company will focus on providing one-stop services from R&D and testing to manufacturing and product launch, establish international exchange channels, accelerate the entry of international medical device products into China, empower Chinese medical device enterprises to expand globally, and jointly promote the development of the global health industry.

Ms. Chen Rong, Deputy Secretary of the CPC Wuzhong District Committee and Mayor of the Wuzhong District People’s Government; Mr. Gu Yuqi, Member of the Standing Committee of the CPC Wuzhong District Committee, Deputy Secretary of the Party Working Committee of Wuzhong Economic and Technological Development Zone, and Deputy Director of its Administrative Committee; Mr. Xu Xing, Member of the Standing Committee of the CPC Wuzhong District Committee and Deputy Mayor of the Wuzhong District People’s Government; Mr. Zhang Lin, Deputy Secretary-General of the China Medical Devices Industry Association; Dr. Yang Qing, Executive Vice President and Chief Business Officer of WuXi AppTec; Mr. Tong Guodong, Chief Operating Officer of WuXi AppTec; and Dr. Liu Fujun, Senior Vice President and Chief Operating Officer of the Testing Business Unit of WuXi AppTec, each delivered remarks and jointly participated in the ribbon-cutting ceremony to mark the completion of the center.

With China’s economic development, an aging population, and the rising incidence of major diseases such as cancer, the domestic medical device industry has experienced rapid growth. The government has introduced a series of favorable policies, laying the foundation for future industrial expansion. However, the industry also faces significant challenges. The widespread application of novel biomaterials has posed new challenges to testing, particularly in the analysis of new material compositions. Many medical devices require both active and passive testing; yet, there is a relative lack of professional expertise in passive testing within China, especially in animal studies. Demand among Chinese physicians for specialized and systematic training in medical device testing is expected to grow rapidly, but high-quality training institutions are severely lacking. As product technologies continue to advance, Chinese medical device manufacturers are increasingly seeking entry into European and American markets, driving growing demand for high-quality, internationally aligned testing and regulatory services.

“WuXi AppTec’s testing platform aims to provide world-class, integrated testing solutions, helping scientists transform their concepts into healthcare products and truly bridge the gap between scientific research and clinical application, thereby benefiting a broad patient population,” said Dr. Liu Fujun.By providing one-stop testing and regulatory services for medical devices, ranging from R&D to commercialization, WuXi AppTec’s Testing Business Unit helps enterprises implement quality control across multiple stages. This enables companies to focus their efforts on the innovative R&D of medical devices, reduce capital waste, and truly empower small and medium-sized enterprises.

The newly inaugurated testing center covers a total area of 15,000 square meters. By comprehensively adopting the capabilities, operational procedures, and quality management systems of WuXi AppTec’s U.S. Medical Device Testing Center, it will provide comprehensive medical device testing services that comply with international quality standards. These services encompass biomaterials analytical toxicology, biocompatibility, risk assessment, microbiological testing for product sterile design, physical testing such as packaging and shelf-life studies, as well as batch release testing. Meanwhile, the center plans to establish a world-class physician training facility to foster close integration among industry, academia, and research, thereby supporting the robust development of China’s medical device industry. In the future, adhering to the principle of seeking truth and practicality, the center will deliver high-standard, high-quality testing and related services to help bring internationally leading healthcare products to patients worldwide and contribute to the rapid advancement of China’s medical device industry.

WuXi AppTec (Stock Code: 603259) is an internationally leading open-access capabilities and technology platform company, providing comprehensive, integrated laboratory research and development (R&D) and manufacturing services for the global pharmaceutical and medical device industries, spanning from drug discovery and development to commercialization. Adhering to its mission of prioritizing research and centering on customers, WuXi AppTec helps global clients shorten R&D cycles and reduce costs for drugs and medical devices through its cost-effective and highly efficient service platform. The company’s platform encompasses R&D and manufacturing of small-molecule drugs, cell and gene therapy R&D and manufacturing, as well as drug and medical device testing. It currently supports thousands of innovative R&D projects for over 3,000 innovative partners across more than 30 countries worldwide. Committed to delivering the latest and best pharmaceutical and healthcare products to patients globally, WuXi AppTec strives to realize its vision of “making it easy to develop drugs and cure diseases.”